756520-66-8

Usage

Uses

Used in Pharmaceutical Industry:
1-(2,6-Dichloro-3-fluorophenyl)ethanol is used as an intermediate in the synthesis of pharmaceuticals for its ability to contribute to the development of new drugs with potential therapeutic properties.
Used in Agrochemical Industry:
1-(2,6-Dichloro-3-fluorophenyl)ethanol is used as an intermediate in the preparation of insecticides and fungicides, playing a key role in the development of agricultural chemicals that protect crops from pests and diseases.
Used in Chemical Synthesis:
1-(2,6-Dichloro-3-fluorophenyl)ethanol is used as a raw material in the manufacture of various chemical products, highlighting its importance in the synthesis of a wide range of compounds.
Used as a Solvent:
Due to its properties, 1-(2,6-Dichloro-3-fluorophenyl)ethanol can be used as a solvent in certain chemical processes, facilitating reactions and improving the efficiency of production.
Safety Precautions:
Given the potential hazards and toxicity associated with 1-(2,6-Dichloro-3-fluorophenyl)ethanol, it is essential to follow proper handling and safety procedures when working with this chemical to minimize risks and ensure the well-being of individuals and the environment.

InChI:InChI=1/C8H7Cl2FO/c1-4(12)7-5(9)2-3-6(11)8(7)10/h2-4,12H,1H3

Upstream product

• 290835-85-7 2',6'-dichloro-3'-fluoroacetophenone 
• 50-99-7 D-glucose 
• 178813-77-9 2,6-dichloro-3-fluorobenzaldehyde 
• 1435-48-9 1,3-dichloro-4-fluorobenzene 

Downstream Products

• 877397-67-6 1-(2,6-dichloro-3-fluorophenyl)ethyl acetate 
• 1040376-43-9 6-chloro-4-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-pyridazin-3-ylamine 
• 1040376-47-3 C₁₄H₁₁Cl₂FN₂O₃ 
• 1229457-91-3 1-(2,6-dichloro-3-fluorophenyl)ethyl methanesulfonate 
• 756503-75-0 5-bromo-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-pyrazin-2-ylamine 
• 877399-13-8 2-(4-(6-amino-5-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)pyridin-3-yl)-1H-pyrazol-1-yl)-2-methylpropanoic acid 
• 877399-36-5 tert-butyl 3-(4-(6-amino-5-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)pyridin-3-yl)-1H-pyrazol-1-yl)azetidine-1-carboxylate 
• 756520-67-9 (±)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)pyridin-2-amine 
• 756503-69-2 (±)-5-bromo-3-(1-(2,6-dichloro-3-fluoropheny)ethoxy)pyridin-2-amine 
• 756520-48-6 5-iodo-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)pyridin-2-amine 
• 877620-62-7 N-(6-amino-5-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-pyridin-3-yl)benzamide 
• 756508-98-2 6-amino-5-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-nicotinonitrile 
• 877620-36-5 3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-methyl-1H-imidazol-4-yl)pyridin-2-amine 

Relevant academic research and scientific papers

AZAINDOLE DERIVATIVE AND USE THEREOF AS FGFR AND C-MET INHIBITOR

A series of pyrazolopymidine derivatives, and use thereof in the preparation of a medicament for treating disease associated with FGFR and c-Met. The pyrazolopymidine derivative is a compound represented by formula (I), a tautomer, or a pharmaceutically acceptable salt thereof.

Ketone Reductase Biocatalysis in the Synthesis of Chiral Intermediates Toward Generic Active Pharmaceutical Ingredients

A range of generic active pharmaceutical ingredients were examined for potential chiral alcohol motifs and derivatives within their structures that could be employed as key synthetic intermediates. For seven generic active pharmaceutical ingredients (APIs), eight precursor ketones were acquired and then subjected to reduction by >400 commercially available ketone reductases from different suppliers. Positive screening results were achieved for five ketones screened, with multiple ketone reductases available for each successful ketone. Selectivity was typically >99.5% ee in most cases, including for the opposite enantiomer. The three best examples were then optimized and quickly scaled up to 1 L scale in high conversion and isolated yield while retaining selectivity of >99.5% ee for the desired chiral alcohol enantiomer. This work illustrates that where a wide range of enzymes are available, productive enzymes to give either alcohol enantiomer can be readily identified for many ketones and rapidly scaled up to produce chiral alcohols. This approach is particularly applicable to generating chiral API intermediates.

Preparation method of deuterated crizotinib and derivatives thereof

The invention relates to a preparation method of deuterated crizotinib and derivatives thereof, and belongs to the technical field of synthesis of medical compounds. Four deuterated crizotinib with different configurations are synthesized, the influence of the deuterated position and different chirality of the deuterated crizotinib on the biological activity and the drug metabolism property of thecrizotinib is investigated, and the result shows that the deuterated crizotinib and the crizotinib have similar anti-cancer activity. Compared with a deuterated crizotinib raceme and crizotinib, thedeuterated crizotinib has certain physicochemical property advantages, has good anticancer application prospects, and provides a new compound for synthesis of novel antitumor drugs. The resolution ofthe racemate phenylethanol derivative is a key step for synthesizing the deuterated crizotinib, the ee value of the racemate phenylethanol derivative directly influences the ee value of a final product, and the resolution method has the characteristics of easiness in operation, low cost and the like.

A (S)-1 - (2, 6 - dichloro -3 - fluoro phenyl) ethanol preparation method

The invention relates to a (S)- 1 - (2, 6 - dichloro - 3 - fluoro phenyl) ethanol preparation method, the 2, 6 - dichloro - 3 - fluoro acetophenone dissolved in ethanol, ethyl acetate extraction four times, saturated salt water washing, drying, to remove the solvent, shall (S)- 1 - (2, 6 - dichloro - 3 - fluorophenyl) ethanol. Chemical separation of the line, in order to phthalic anhydride for separating material, (S)- 1 - phenylethylamine as the resolving agent, effectively improves the yield and purity of the product.

Design, synthesis and structure-activity relationship study of aminopyridine derivatives as novel inhibitors of Janus kinase 2

Janus Kinase 2 (JAK2) is a kind of intracellular non-receptor protein tyrosine kinase and has been certified as an important target for the treatment of myeloproliferative neoplasms and rheumatoid arthritis. However, the low selectivity and potential safety issues restrict the clinical applications of JAK2 inhibitors. Here we found that crizotinib showed good inhibitory activity against JAK2 by enzymatic assays (IC50 = 27 nM). Then we carried out structure-based drug design and synthesized a series of compounds with an aminopyridine scaffold. Finally, compound 12k and 12l were identified as the promising inhibitors of JAK2, which exhibited high inhibitory activity (IC50 = 6 nM and 3 nM, respectively) and selectivity for JAK2 over JAK1 and JAK3, and showed potent antiproliferative activities toward HEL human erythroleukemia cells. Moreover, 12k suppressed symptoms of the collagen-induced arthritis (CIA) model in rats.

Alkenyl compound and its method and use thereof

The invention provides a new substituted alkenyl compound, pharmaceutically acceptable salts of the new substituted alkenyl compound, a medicinal preparation of the new substituted alkenyl compound, and application of the new substituted alkenyl compound, the pharmaceutically acceptable salts and the medicinal preparation of the new substituted alkenyl compound in aspects of regulating the activity of protein kinase and regulating the intercellular or intracellular signal response. The invention also relates to a medicament composition containing the compound at the same time, and relates to a method for treating high-proliferative diseases of mammals especially the human by using the medicament composition.

An anti-tumor molecule targeting drug [...] process for the synthesis of

The invention provides a synthetic process method for a novel antineoplastic molecular targeted drug of crizotinib, and relates to the resolution process optimization of chiral isomers of a crizotinib precursor and the recycling of by-products. The method adopts a catalyzing resolution method that Boc-L-proline, namely, N-(tert-butoxycarbonyl)-L-proline) is combined with a catalyst of p-toluenesulfonic acid and a condensating agent of 1-(3-Dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride to split 1-(2,6-dichloro-3-fluorophenyl)ethanol racemate into S-type alcohol and R-type alcohol, and a resolution by-product mixture is subjected to hydrolysis and configuration transition to obtain the (S)-1-(2,6-dichloro-3-fluorophenyl)ethanol; the total yield is improved to 76% from 30%, the time is shortened, pollution is reduced, and application to industrialized production is easy.

Preferential crystallization preparation method of chiral alpha-phenylethyl alcohol

The invention discloses a method for preparing chiral alpha-phenylethyl alcohol. The method is a preferential crystallization method implemented by taking petroleum ether as a solved, is simple and convenient to operate, is high in product yield and purit

CRIZOTINIB FOR USE IN THE TREATMENT OF CANCER

The present invention relates to the use of ROS kinase inhibitors for treating abnormal cell growth in mammals. In particular, the invention provides methods of treating mammals suffering from cancer mediated by at least one genetically altered ROS. In particular, the invention provides methods of treating mammals suffering from cancer mediated by at least one genetically altered ROS by administration of crizotinib.

Synthesis process for compound crizotinib

The invention provides a new synthesis method for crizotinib. An atomic economic reaction is adopted to reduce environmental pollution. A high-optical purity raw material is obtained by chiral prolinol induced chiral reduction; a chiral centre is constructed through an SN2 substitution reaction; post-processing and purification difficulties caused by Mitsunobu reaction are overcome. Malononitrile derivative is constructed by adopting a coupling reaction of malononitrile and bromo-pyridinium derivative; N,N-dicarboamide derivatives are obtained by performing aminolysis on N,N-dimethylamine hydrochloride; in the N,N-dicarboamide derivatives, N,N-dimethylamine serving as an easy-to-leave group and hydrazine perform a ring closing reaction to construct a pyrazolone ring, so that an expected final product, namely crizotinib, is obtained. According to the method, though continuous steps are used, the reaction of each step is high, the optical purity is high, and the total yield is also high. In addition, raw materials used in the synthesis method are low in cost and easily obtained; the using amount of a catalyst is small; total cost is easy to control. An operating process is simple and convenient and easy to control, and is suitable for industrial production.